Spots Global Cancer Trial Database for refractory high risk myelodysplastic syndrome
Every month we try and update this database with for refractory high risk myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | NCT03383575 | Acute Myeloid L... Blasts 20-30 Pe... Chronic Myelomo... IDH2 Gene Mutat... Myelodysplastic... Recurrent High ... Refractory High... | Azacitidine Enasidenib Quality-of-Life... | 12 Years - | M.D. Anderson Cancer Center | |
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | NCT03896269 | Blasts 10-19 Pe... Blasts More Tha... High Risk Chron... Recurrent Chron... Recurrent High ... Refractory Chro... Refractory High... | Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | NCT03359460 | Myelodysplastic... Previously Trea... Refractory High... Secondary Myelo... Therapy-Related... | Ibrutinib Lenalidomide | 18 Years - | University of California, Davis |